Sinopharm Group Co. Ltd. (HKG:1099)
Hong Kong
· Delayed Price · Currency is HKD 20.56
+0.10 (0.49%)
At close: Dec 5, 2025
Sinopharm Group Revenue
Sinopharm Group had revenue of 145.44B CNY in the quarter ending September 30, 2025, a decrease of -1.37%. This brings the company's revenue in the last twelve months to 573.56B, down -3.29% year-over-year. In the year 2024, Sinopharm Group had annual revenue of 584.51B, down -2.02%.
Revenue (ttm)
573.56B CNY
Revenue Growth
-3.29%
P/S Ratio
0.10
Revenue / Employee
5.30M CNY
Employees
108,217
Market Cap
64.16B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 584.51B | -12.06B | -2.02% |
| Dec 31, 2023 | 596.57B | 44.42B | 8.05% |
| Dec 31, 2022 | 552.15B | 31.10B | 5.97% |
| Dec 31, 2021 | 521.05B | 64.64B | 14.16% |
| Dec 31, 2020 | 456.41B | 31.14B | 7.32% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 38.69B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
Sinopharm Group News
- 6 months ago - Hong Kong stocks waver on China’s mixed economic data - South China Morning Post
- 8 months ago - Sinopharm Group: Mixed Read-Throughs From Peer Disclosures And Management Guidance - Seeking Alpha
- 1 year ago - Sinopharm Group: The Focus Is On Working Capital And Profitability - Seeking Alpha
- 1 year ago - How AI and Sinopharm’s disruptive technologies are contributing to longer human life - The Times of India
- 4 years ago - Pandemic Accelerates China's Drive Into mRNA Treatments - Seeking Alpha
- 4 years ago - Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines - Seeking Alpha
- 5 years ago - Diversifying Into Top-Ranked Sinopharm - Seeking Alpha
- 5 years ago - Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines - Seeking Alpha